α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: R. Paniagua, Melissa Reeves, F. Arce Vargus, Julia Malato, A. Mirza, Hidetoshi Mori, Rosemary J. Akhurst, M. Adoumie, Mikhail Binnewies, Byron Hann, B. Liang, Michael Rosenblum, O. Li, Minh D. To, Miranda Broz, Dominique S. Meyer, D. Sheppard, Sergio A. Quezada, Allan Balmain, T. Buchmann, Di Wu, Matthew F. Krummel, Eswari Dodagatta-Marri, R. del Rosario

Publikováno v: Journal for immunotherapy of cancer, vol 7, iss 1
Dodagatta-Marri, E; Meyer, DS; Reeves, MQ; Paniagua, R; To, MD; Binnewies, M; et al.(2019). α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.. Journal for immunotherapy of cancer, 7(1), 62. doi: 10.1186/s40425-018-0493-9. UCSF: Retrieved from: http://www.escholarship.org/uc/item/28t115w7
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)

Background Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1601fcdaed83828a09f9e659c007e4fb
https://escholarship.org/uc/item/28t115w7

Additional file 3: of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: E. Dodagatta-Marri, D. Meyer, M. Reeves, R. Paniagua, M. To, M. Binnewies, M. Broz, H. Mori, D. Wu, M. Adoumie, R. Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. Hann, A. Mirza, S. Quezada, M. Rosenblum, M. Krummel, A. Balmain, R. Akhurst

Figure S1. Growth responses of CCK62 and GEK1428 to immunotherapy. Figure S2. CCK168 responses to α-PD-1 and/or α-TGFβ. Figure S3. α-TGFβ and α-TGFβ/α-PD-1 combination therapy elicit long-term tumor immunity to Kras-driven tumors. Figure S4.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fa321eec4572986f53c2caf933bab5f

Additional file 1: of α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Autor: E. Dodagatta-Marri, D. Meyer, M. Reeves, R. Paniagua, M. To, M. Binnewies, M. Broz, H. Mori, D. Wu, M. Adoumie, R. Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. Hann, A. Mirza, S. Quezada, M. Rosenblum, M. Krummel, A. Balmain, R. Akhurst

Supplementary Methods. (DOCX 9 kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcfa50cc4b3c768e7fe73dbae2c6dd24

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.

Autor: Dodagatta-Marri E; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Meyer DS; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Reeves MQ; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Paniagua R; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA.; Department of Dermatology, UCSF, San Francisco, CA, USA., To MD; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Binnewies M; Department of Pathology, UCSF, San Francisco, CA, USA., Broz ML; Department of Pathology, UCSF, San Francisco, CA, USA., Mori H; Center for Comparative Medicine UC Davis, Davis, CA, USA., Wu D; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Adoumie M; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Del Rosario R; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Li O; Department of Medicine, UCSF, San Francisco, CA, USA., Buchmann T; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Liang B; Xoma Corporation, Berkeley, CA, USA., Malato J; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Arce Vargus F; Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK., Sheppard D; Xoma Corporation, Berkeley, CA, USA., Hann BC; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA., Mirza A; Department of Medicine, UCSF, San Francisco, CA, USA., Quezada SA; Cancer Immunology Unit, Immune Regulation and Tumour Immunotherapy Lab, University College London, London, UK., Rosenblum MD; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA.; Department of Dermatology, UCSF, San Francisco, CA, USA., Krummel MF; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA.; Department of Pathology, UCSF, San Francisco, CA, USA.; UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Balmain A; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA.; UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, UCSF, San Francisco, CA, USA., Akhurst RJ; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA, USA. Rosemary.akhurst@ucsf.edu.; UCSF Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Rosemary.akhurst@ucsf.edu.; Department of Anatomy, UCSF, San Francisco, CA, USA. Rosemary.akhurst@ucsf.edu.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Mar 04; Vol. 7 (1), pp. 62. Date of Electronic Publication: 2019 Mar 04.